Consistently, Hu et al. [16] demonstrated that IMP2 inhibition suppressed cell proliferation and that high IMP2 expression was associated with worse clinical outcomes in patients with pancreatic cancer. Here, IGF2BP2 is linked to familial pancreatic carcinoma.